DON'T FORGET ABOUT TOMORROW! A NOT-TO-BE-MISSED MEETING FOR THOSE WHO WANT TO KNOW THE LATEST RESEARCH INTO HIV RESERVOIRS DR. LISA FRENKEL WILL TALK ABOUT HER WORK DONE HERE IN...
Happy Monday –
Here is some interesting news that came from NIH that might offer a new approach to treating some viral infections like the flu or HIV.
Two siblings with a rare genetic disorder that affects the way their bodies attach sugars to proteins seem to have some protection from certain viral infections.
Figuring out what was going on for these two children has made a discovery that sounds like it holds some promise for a new way to interrupt the HIV life cycle.
Below is the press release from NIH, and attached for you is the paper that appeared in the New England Journal of Medicine.
Study could offer clues for developing new antiviral treatments
Saturday 12 April 2014 – 12am PST
A National Institutes of Health (NIH) study reports that a rare genetic disease, while depleting patients of infection-fighting antibodies, may actually protect them from certain severe or recurrent viral infections.
Researchers found that HIV and influenza viruses replicate in the cells of people with congenital disorder of glycosylation type IIb (CDG-IIb) at a much lower rate than in healthy donor cells, creating fewer and less infectious viruses.
The study, published in The New England Journal of Medicine, was led by Sergio Rosenzweig, M.D., Ph.D., director of the Primary Immune Deficiency (PID) Clinic at the NIH’s National Institute of Allergy and Infectious Diseases (NIAID).
In the study, the researchers diagnosed CDG-IIb in two siblings with severe development issues who were referred to the NIAID PID Clinic though the NIH Undiagnosed Diseases Program.
CDG-IIb is extremely rare, with only one other case reported.
The genetic defect of the disease disrupts glycosylation, or the process of attaching sugars to proteins.
As a result, proteins called gamma globulins, which include infection-fighting antibodies, are unstable and persist at low levels in the patients’ blood.
Interestingly, some viruses, including HIV and influenza, depend on glycosylation to form protective shields.
The researchers showed that these viruses were less able to replicate or create protective shields because of the glycosylation defects in CDG-IIb cells.
In comparison, adenovirus, poliovirus and vaccinia virus, which either do not rely on glycosylation or do not form protective shields, replicated normally when added to both CDG-IIb and healthy cells.
This study suggests that modulating aspects of host glycosylation may be a strategy to control certain viral infections.
Outreach Coordinator/UW ACTU
CAB Coordinator / defeatHIV
Community Engagement Officer / UW CFAR
Twitter – https://twitter.com/actgnetwork
YouTube – http://www.youtube.com/actgnetwork
Tumblr – http://actgnetwork.tumblr.com/
Instagram – @actgnetwork
Twitter – https://twitter.com/defeathiv #defeatHIV
YouTube – http://www.youtube.com/defeathiv
The above email may contain patient identifiable or confidential
information. Because email is not secure, please be aware of
associated risks of email transmission. If you are a patient,
communicating to a UW Medicine Provider via email implies
your agreement to email communication; see
The information is intended for the individual named above. If
you are not the intended recipient, any disclosure, copying,
distribution or use of the contents of this information is prohibited.
Please notify the sender by reply email, and then destroy all copies
of the message and any attachments. See our Notice of Privacy
Practices at www.uwmedicine.org